Get the Stockscreener App
0.54
6.15%
0.0313
After Hours:
.54
Fractyl Health Inc stock is traded at $0.54, with a volume of 1.47M.
It is up +6.15% in the last 24 hours and up +16.00% over the past month.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
See More
Previous Close:
$0.5087
Open:
$0.5145
24h Volume:
1.47M
Relative Volume:
0.30
Market Cap:
$85.67M
Revenue:
$3,000
Net Income/Loss:
$-140.95M
P/E Ratio:
-0.2641
EPS:
-2.0449
Net Cash Flow:
$-90.89M
1W Performance:
+16.10%
1M Performance:
+16.00%
6M Performance:
-59.40%
1Y Performance:
-53.04%
1-Day Range:
$0.4947
$0.54
1-Week Range:
$0.4481
$0.54
52-Week Range:
$0.3772
$3.03
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.54 | 80.70M | 3,000 | -140.95M | -90.89M | -2.0449 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-28-25 | Initiated | Ladenburg Thalmann | Buy |
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
View All
Fractyl Health Inc Stock (GUTS) Latest News
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
Buy Signal: Is Fractyl Health Inc undervalued by DCF analysisDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
GUTS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GUTS Stock Price, Quote & Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health Q4 2025 Earnings Call Transcript - MarketBeat
Portfolio Shifts: Is Fractyl Health Inc undervalued by DCF analysis2026 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Fractyl Health, Inc. (GUTS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Pharma News: Is Fractyl Health Inc benefiting from interest rate changes2026 Big Picture & Growth Oriented Trading Recommendations - baoquankhu1.vn
Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fractyl Health Earnings Call: Revita Nears Key Pivotal Test - The Globe and Mail
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
HC Wainwright Forecasts Fractyl Health Q1 Earnings - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Market Recap: Is Fractyl Health Inc in a long term uptrend2026 Volume & Low Risk High Reward Ideas - baoquankhu1.vn
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Decreases By 55.7% - MarketBeat
Fractyl Health (NASDAQ:GUTS) Earns Buy Rating from Canaccord Genuity Group - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN) - The Globe and Mail
Fractyl Health FY2029 EPS Forecast Lifted by HC Wainwright - MarketBeat
Fractyl Health Faces Significant Compliance Risks Under Global Anti-Corruption and Sanctions Laws - TipRanks
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating - Moomoo
Fractyl Highlights Revita Progress and 2025 Financial Results - The Globe and Mail
Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know - Benzinga
Fractyl Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - ca.investing.com
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 - MSN
Disease-Modifying Therapies for Obesity and Type 2 Diabetes: Revita and Rejuva Pipeline Overview - Minichart
Fractyl Health Inc’s 2025 Q4 Call: CPT Code Timing, Regulatory Readiness, and Ablation Targets Don’t Align - Bitget
GUTS: Pivotal study enrollment complete; Revita advances toward key 2026 data and de novo submission - TradingView
Fractyl Health Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fractyl Health Q4 2025 sees cost cut, stock dips - Investing.com
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout - ChartMill
FRACTYL HEALTH ($GUTS) Releases Q4 2025 Earnings - Quiver Quantitative
Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fractyl Health 2025 10-K: $0M Revenue, Net Loss $140.954M - TradingView
Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans - Stock Titan
Fractyl Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fractyl Health (Nasdaq: GUTS) widens 2025 loss but advances pivotal Revita - Stock Titan
Fractyl Health, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Fractyl Health, Inc. (GUTS) loses 77.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fractyl Health (NASDAQ:GUTS) - intelligentinvestor.com.au
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target - Insider Monkey
Fractyl Health, Inc. (GUTS) moves to buy: Rationale behind the upgrade - MSN
Fractyl Health Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning - Stock Titan
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):